In yesterday’s Wall Street session, Sangamo Therapeutics Inc. (NASDAQ:SGMO) shares traded at $1.44, up 0.70% from the previous session.
11 analysts cover Sangamo Therapeutics Inc. (NASDAQ:SGMO), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $16.00 and a low of $1.50, we find $8.00. Given the previous closing price of $1.43, this indicates a potential upside of 459.44 percent. SGMO stock price is now 12.99% away from the 50-day moving average and -47.19% away from the 200-day moving average. The market capitalization of the company currently stands at $230.93M.
The stock has received a hold rating from 2 analysts and a buy rating from 7. Brokers who have rated the stock have averaged $7.38 as their price target over the next twelve months.
With the price target reduced from $5 to $1.50, BofA Securities Downgraded its rating from Neutral to Underperform for Sangamo Therapeutics Inc. (NASDAQ: SGMO).
In other news, BIOGEN INC., 10% Owner sold 100,000 shares of the company’s stock on Aug 30. The stock was sold for $526,520 at an average price of $5.27. Upon completion of the transaction, the 10% Owner now directly owns 23,652,466 shares in the company, valued at $34.06 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 29, 10% Owner BIOGEN INC. sold 400,000 shares of the business’s stock. A total of $2,130,720 was realized by selling the stock at an average price of $5.33. This leaves the insider owning 23,752,466 shares of the company worth $34.2 million. Insiders disposed of 633,100 shares of company stock worth roughly $0.91 million over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SGMO stock. A new stake in Sangamo Therapeutics Inc. shares was purchased by HRT FINANCIAL LP during the first quarter worth $697,000. ACADIAN ASSET MANAGEMENT LLC invested $674,000 in shares of SGMO during the first quarter. In the first quarter, CANDRIAM S.C.A. acquired a new stake in Sangamo Therapeutics Inc. valued at approximately $292,000. PRUDENTIAL FINANCIAL INC acquired a new stake in SGMO for approximately $235,000. PROFUND ADVISORS LLC purchased a new stake in SGMO valued at around $165,000 in the second quarter. In total, there are 260 active investors with 61.50% ownership of the company’s stock.
On Thursday morning Sangamo Therapeutics Inc. (NASDAQ: SGMO) stock kicked off with the opening price of $1.4300. During the past 12 months, Sangamo Therapeutics Inc. has had a low of $1.07 and a high of $6.42. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.90, and a quick ratio of 3.90. The fifty day moving average price for SGMO is $1.2732 and a two-hundred day moving average price translates $2.7092 for the stock.
The latest earnings results from Sangamo Therapeutics Inc. (NASDAQ: SGMO) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at $0.12, beating analysts’ expectations of -$0.33 by 0.45. This compares to -$0.30 EPS in the same period last year. The net profit margin was -52.80% and return on equity was -40.40% for SGMO. The company reported revenue of $157.96 million for the quarter, compared to $28.23 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 459.52 percent. For the current quarter, analysts expect SGMO to generate $14.83M in revenue.
Sangamo Therapeutics Inc.(SGMO) Company Profile
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
